Opendata, web and dolomites

Pregnolia SIGNED

A Diagnostic Medical Device Determining the Risk of Preterm Birth

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "Pregnolia" data sheet

The following table provides information about the project.

Coordinator
PREGNOLIA AG 

Organization address
address: WIESENSTRASSE 33
city: SCHLIEREN
postcode: 8952
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 1˙834˙162 €
 EC max contribution 1˙283˙913 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2021-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PREGNOLIA AG CH (SCHLIEREN) coordinator 1˙283˙913.00

Map

 Project objective

Premature birth (birth before 37 weeks of pregnancy) is a global, yet unsolved, problem. With a global amount of 14.94 M babies born prematurely, PTB is the leading cause of neonatal and infant mortality globally, and those who survive often have breathing problems, cerebral palsy, intellectual disabilities and other lifelong problems. On top of the associated suffering and societal long-term consequences, PTB is associated with more than €50,000 in healthcare costs per premature baby, which translates into total yearly costs for the healthcare system of €20 billion in Europe, and €23 billion in USA. Pregnolia is a unique diagnostic device to determine the risk of PTB based on the measurements of cervical tissue stiffness. Our patented device has twice the sensitivity of the current “gold standard” (ultrasounds), it is simple, safe, and easy to use and to integrate into routine gynaecological consultations. With our solution, the majority of women, 80% out of 100% at risk, can be treated to prevent premature birth. This phase 2 project has been defined to upgrade Pregnolia’s prototype based on our Feasibility Study outcomes, which will allow us to fulfil our clinical and commercial goals by delivering an innovative and cost-effective diagnostic device for addressing the unmet need of PTB, while sustaining a viable commercial model. Pregnolia will achieve net revenues of ~€74 M, net profits of ~€30 M and, considering the investment of €8.8M, a ROI of ~7 euro per euro invested at year 5. Thanks to Pregnolia, we estimate a potential reduction of PTBs costs by 42% (up to ~€8.4 billion in EU, €9.66bn in USA). Furthermore, our Pregnolia device will impact on the reduction of children’s health complications and child deaths.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PREGNOLIA" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PREGNOLIA" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More  

Totem Spoon (2019)

Interactive Digital Signage with emotional intelligence for smart cities

Read More